mChIP-seq for multiplex epigenomic profiling uncovers cancer-specific histone features in cellular and circulating nucleosomes.
Blood tests detecting multiple cancer-associated histone marks distinguished breast cancer patients from healthy controls, potentially enabling earlier detection through simple blood draws.
mChIP-seq simultaneously profiles 11 histone modifications across cancer cell lines revealing reduced H2A.Z-H3K4me3 correlation in cancer; extended to cell-free plasma (cf-mChIP-seq), multiplex profiling of H2A.Z, H3K4me3, H3K27ac, and H3K9me3 in circulating nucleosomes distinguished breast cancer from healthy controls. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Methods development / proof-of-concept
- Category
- early_cancer_detection
- Maturity
- Validated
- Journal
- Cell Rep Methods
Why it surfaced
Novel Cell Reports Methods paper introducing multiplex epigenomic profiling of circulating nucleosomes as a multi-dimensional liquid biopsy approach; technically sound with breast cancer human sample validation and strong potential for pan-cancer early detection and tissue-of-origin inference.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.